Raymond James Financial started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued a strong-buy rating and a $28.00 target price on the stock. Several other brokerages also recently commented on PHAT. Weiss Ratings restated a “sell (d-)” rating […]